Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
16. Dezember 2022 06:30 ET
|
Diffusion Pharmaceuticals Inc.
LifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting New Director to be...
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
14. November 2022 06:30 ET
|
Diffusion Pharmaceuticals Inc.
Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of...
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
25. Oktober 2022 06:30 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
26. Juli 2022 07:30 ET
|
Diffusion Pharmaceuticals Inc.
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)...
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
23. Juni 2022 07:30 ET
|
Diffusion Pharmaceuticals Inc.
Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise intervalPositive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to...
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523
01. Dezember 2021 07:02 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...